Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.
A major component of a US Army Medical Research and Development Command-supported program to discover and develop new drugs for the treatment of Rift Valley fever, sandfly fever, and Crimean-Congo hemorrhagic fever has been to study candidate test materials against hepatotropic infections of C57BL/6 mice induced by the related but less biohazardous Punta Toro virus (PTV). The effects of 75 compounds, some of which were considered immunomodulators in their primary mechanism of activity, were studied in the PTV infection model. Of these, ribavirin, ribamidine, ribavirin 2',3',5'-triacetate, tiazofurin, tiazofurin-5'-monophosphate, tiazofurin-2',3',5'-triacetate, selenazofurin, pyrazofurin, 3-deazaguanine, and 3-deazaguanosine were considered significantly inhibitory, acting against the infection by a direct antiviral (non-immunomodulatory) fashion. These compounds had therapeutic indices (TI) ranging from > or = 5 to 65, using increased survivors as the evaluation parameter. Immunomodulators considered significantly inhibitory to this infection were poly (ICLC), ampligen, human recombinant interferon-alpha-A/D, MVE-1, MVE-2, AM-3, AM-5, mannozym, bropirimine, CL246,738, phenyleneamine, and 7-thia-8-oxoguanosine. Utilizing increased survivor numbers as measure of activity, these inhibitors had TI ranging from > or = 16 to 1000. Other antiviral effects exerted by the active compounds included reduction of hepatic icterus, lowered serum glutamic oxaloacetic and pyruvic acid transaminases, and inhibition of recoverable serum and liver virus titers. The active immunomodulators were significantly effective when therapy was initiated as late as 48 h after virus inoculation, at a time when clinical signs of the PTV disease were being manifested in the animal.
Sidwell
R W
RW
Institute for Antiviral Research, Utah State University, Logan 84322-5600.
Huffman
J H
JH
Barnard
D L
DL
Smee
D F
DF
Warren
R P
RP
Chirigos
M A
MA
Kende
M
M
Huggins
J
J
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D002044:Bunyaviridae Infections / Q000188:drug therapy* / Q000201:enzymology / Q000628:therapy; D004353:Drug Evaluation, Preclinical; D008099:Liver / Q000201:enzymology / Q000821:virology; D051379:Mice; D008810:Mice, Inbred C57BL; D016856:Phlebovirus / Q000187:drug effects*; D012449:Safety
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase